Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials-Reference-Cited by-同舟云学术

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

Published:2023-01 Issue: Volume:55 Page:101737
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Verma Subodh^ORCID,Bhatta Meena,Davies Melanie,Deanfield John E.,Garvey W. Timothy,Jensen Camilla,Kandler Kristian,Kushner Robert F.,Rubino Domenica M.,Kosiborod Mikhail N.

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review;Mechanick;J Am Coll Cardiol,2020

2. Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice;Avan;J Cell Physiol,2018

3. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection;Ridker;Circ Res,2016

4. New markers of inflammation and endothelial cell activation: part I;Szmitko;Circulation,2003

5. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?;Ridker;Circulation,2020

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases;Metabolism;2024-10

2. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial;JMIR Research Protocols;2024-09-13

3. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study;eClinicalMedicine;2024-08

4. Inflammation in Obesity-Related HFpEF;Journal of the American College of Cardiology;2024-08

5. Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients;Cureus;2024-07-16